261 related articles for article (PubMed ID: 24956445)
1. Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models.
Wang N; Docherty FE; Brown HK; Reeves KJ; Fowles AC; Ottewell PD; Dear TN; Holen I; Croucher PI; Eaton CL
J Bone Miner Res; 2014 Dec; 29(12):2688-96. PubMed ID: 24956445
[TBL] [Abstract][Full Text] [Related]
2. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
3. Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases.
Watanabe K; Tominari T; Hirata M; Matsumoto C; Maruyama T; Murphy G; Nagase H; Miyaura C; Inada M
Biochem Biophys Res Commun; 2016 Sep; 478(1):154-161. PubMed ID: 27450806
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Conley-LaComb MK; Semaan L; Singareddy R; Li Y; Heath EI; Kim S; Cher ML; Chinni SR
Mol Cancer; 2016 Nov; 15(1):68. PubMed ID: 27809841
[TBL] [Abstract][Full Text] [Related]
5. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS
J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826
[TBL] [Abstract][Full Text] [Related]
6. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
[TBL] [Abstract][Full Text] [Related]
7. The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.
Özdemir BC; Hensel J; Secondini C; Wetterwald A; Schwaninger R; Fleischmann A; Raffelsberger W; Poch O; Delorenzi M; Temanni R; Mills IG; van der Pluijm G; Thalmann GN; Cecchini MG
PLoS One; 2014; 9(12):e114530. PubMed ID: 25485970
[TBL] [Abstract][Full Text] [Related]
8. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.
Brizuela L; Martin C; Jeannot P; Ader I; Gstalder C; Andrieu G; Bocquet M; Laffosse JM; Gomez-Brouchet A; Malavaud B; Sabbadini RA; Cuvillier O
Mol Oncol; 2014 Oct; 8(7):1181-95. PubMed ID: 24768038
[TBL] [Abstract][Full Text] [Related]
9. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.
Chinni SR; Yamamoto H; Dong Z; Sabbota A; Bonfil RD; Cher ML
Mol Cancer Res; 2008 Mar; 6(3):446-57. PubMed ID: 18337451
[TBL] [Abstract][Full Text] [Related]
10. Mitotic quiescence, but not unique "stemness," marks the phenotype of bone metastasis-initiating cells in prostate cancer.
Wang N; Docherty F; Brown HK; Reeves K; Fowles A; Lawson M; Ottewell PD; Holen I; Croucher PI; Eaton CL
FASEB J; 2015 Aug; 29(8):3141-50. PubMed ID: 25888599
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
12. Niche competition and cancer metastasis to bone.
Schuettpelz LG; Link DC
J Clin Invest; 2011 Apr; 121(4):1253-5. PubMed ID: 21436576
[TBL] [Abstract][Full Text] [Related]
13. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
14. Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.
Yu-Lee LY; Yu G; Lee YC; Lin SC; Pan J; Pan T; Yu KJ; Liu B; Creighton CJ; Rodriguez-Canales J; Villalobos PA; Wistuba II; de Nadal E; Posas F; Gallick GE; Lin SH
Cancer Res; 2018 Jun; 78(11):2911-2924. PubMed ID: 29514796
[TBL] [Abstract][Full Text] [Related]
15. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
17. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
18. The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer.
Wang N; Reeves KJ; Brown HK; Fowles AC; Docherty FE; Ottewell PD; Croucher PI; Holen I; Eaton CL
J Exp Clin Cancer Res; 2015 Oct; 34():124. PubMed ID: 26480944
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of osteoblastic bone metastases from prostate cancer.
Ibrahim T; Flamini E; Mercatali L; Sacanna E; Serra P; Amadori D
Cancer; 2010 Mar; 116(6):1406-18. PubMed ID: 20108337
[TBL] [Abstract][Full Text] [Related]
20. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.
Darash-Yahana M; Pikarsky E; Abramovitch R; Zeira E; Pal B; Karplus R; Beider K; Avniel S; Kasem S; Galun E; Peled A
FASEB J; 2004 Aug; 18(11):1240-2. PubMed ID: 15180966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
